I've put together a full literature review, all the key papers, mechanism data, TGA and FDA regulatory status, and safety profile
Because GCLC floxed X Iba1-Cre mice died early (around 34 months of age) due to developmental defects, we could not assess the effect of microglial GCLC-deficiency on brain atrophy
Therapeutic effects of adipose-derived mesenchymal stem cells combined with glymphatic system activation in prion disease
Conflicts of interest The authors declare that there are no conflicts of interest
For example, researchers from a 2016 review of data on the gut-brain axis and BPC-157 explain that the peptide could maintain gastrointestinal mucosa, modulate serotonergic and dopaminergic systems, regenerate peripheral nerves, protect certain neurons, counteract various types of lesions, promote wound healing, and more.7 Some of these possible benefits are due to BPC-157s promotion of the cell migration of vascular endothelial cells.24 This means that the peptide can encourage the formation of new blood vessels (also known as angiogenesis)